Type to search

Gracell Biotechnologies Unveils Innovation Center in U.S. | Pharmtech Focus
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors | Pharmtech Focus
Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer | Pharmtech Focus